ID   NFX1_HUMAN              Reviewed;        1120 AA.
AC   Q12986; A8K6H8; Q5VXW6; Q96EL5; Q9BXI1;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   20-MAY-2008, sequence version 2.
DT   07-APR-2021, entry version 197.
DE   RecName: Full=Transcriptional repressor NF-X1;
DE            EC=2.3.2.-;
DE   AltName: Full=Nuclear transcription factor, X box-binding protein 1;
GN   Name=NFX1; Synonyms=NFX2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Testis;
RA   Li J.M., Sah J.H., Zhou Z.M.;
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 48-1120 (ISOFORM 1).
RX   PubMed=7964459; DOI=10.1084/jem.180.5.1763;
RA   Song Z., Krishna S., Thanos D., Strominger J.L., Ono S.J.;
RT   "A novel cysteine-rich sequence-specific DNA-binding protein interacts with
RT   the conserved X-box motif of the human major histocompatibility complex
RT   class II genes via a repeated Cys-His domain and functions as a
RT   transcriptional repressor.";
RL   J. Exp. Med. 180:1763-1774(1994).
RN   [7]
RP   FUNCTION AS AN E2-DEPENDENT UBIQUITIN-PROTEIN LIGASE.
RX   PubMed=10500182; DOI=10.1073/pnas.96.20.11364;
RA   Lorick K.L., Jensen J.P., Fang S., Ong A.M., Hatakeyama S., Weissman A.M.;
RT   "RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent
RT   ubiquitination.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:11364-11369(1999).
RN   [8]
RP   INTERACTION WITH HPV16 E6 (MICROBIAL INFECTION), AND FUNCTION.
RX   PubMed=15371341; DOI=10.1101/gad.1214704;
RA   Gewin L., Myers H., Kiyono T., Galloway D.A.;
RT   "Identification of a novel telomerase repressor that interacts with the
RT   human papillomavirus type-16 E6/E6-AP complex.";
RL   Genes Dev. 18:2269-2282(2004).
RN   [9]
RP   FUNCTION, INTERACTION WITH PABPC1 AND PABPC4, AND MUTAGENESIS OF PHE-20.
RX   PubMed=17267499; DOI=10.1128/jvi.02007-06;
RA   Katzenellenbogen R.A., Egelkrout E.M., Vliet-Gregg P., Gewin L.C.,
RA   Gafken P.R., Galloway D.A.;
RT   "NFX1-123 and poly(A) binding proteins synergistically augment activation
RT   of telomerase in human papillomavirus type 16 E6-expressing cells.";
RL   J. Virol. 81:3786-3796(2007).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-50; SER-95; SER-150 AND
RP   SER-326, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: Binds to the X-box motif of MHC class II genes and represses
CC       their expression. May play an important role in regulating the duration
CC       of an inflammatory response by limiting the period in which MHC class
CC       II molecules are induced by interferon-gamma. Isoform 3 binds to the X-
CC       box motif of TERT promoter and represses its expression. Together with
CC       PABPC1 or PABPC4, isoform 1 acts as a coactivator for TERT expression.
CC       Mediates E2-dependent ubiquitination. {ECO:0000269|PubMed:10500182,
CC       ECO:0000269|PubMed:15371341, ECO:0000269|PubMed:17267499}.
CC   -!- SUBUNIT: Isoform 1 interacts with PABPC1 and PABPC4.
CC       {ECO:0000269|PubMed:17267499}.
CC   -!- SUBUNIT: (Microbial infection) Isoform 1 and isoform 3 interact with
CC       human papillomavirus (HPV) type-16 E6 oncoprotein.
CC       {ECO:0000269|PubMed:15371341}.
CC   -!- INTERACTION:
CC       Q12986; P54253: ATXN1; NbExp=3; IntAct=EBI-2130062, EBI-930964;
CC       Q12986; G5E9A7: DMWD; NbExp=3; IntAct=EBI-2130062, EBI-10976677;
CC       Q12986; P14136: GFAP; NbExp=3; IntAct=EBI-2130062, EBI-744302;
CC       Q12986; P28799: GRN; NbExp=3; IntAct=EBI-2130062, EBI-747754;
CC       Q12986; P02545: LMNA; NbExp=3; IntAct=EBI-2130062, EBI-351935;
CC       Q12986; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-2130062, EBI-5235340;
CC       Q12986; Q86WV8: TSC1; NbExp=3; IntAct=EBI-2130062, EBI-12806590;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=NFX-123;
CC         IsoId=Q12986-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q12986-2; Sequence=VSP_033684, VSP_033685;
CC       Name=3; Synonyms=NFX-91;
CC         IsoId=Q12986-3; Sequence=VSP_033682, VSP_033683;
CC   -!- INDUCTION: By IFNG/IFN-gamma.
CC   -!- DOMAIN: The RING-type zinc finger domain interacts with an ubiquitin-
CC       conjugating enzyme (E2) and facilitates ubiquitination.
CC   -!- PTM: Isoform 3 is polyubiquitinated in the presence of HPV16 E6
CC       protein; which leads to proteasomal degradation. Isoform 1 is not
CC       polyubiquitinated.
CC   -!- SIMILARITY: Belongs to the NFX1 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA69517.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF332009; AAK16545.1; -; mRNA.
DR   EMBL; AK291643; BAF84332.1; -; mRNA.
DR   EMBL; AL356472; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356218; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471071; EAW58510.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58511.1; -; Genomic_DNA.
DR   EMBL; BC012151; AAH12151.1; -; mRNA.
DR   EMBL; U15306; AAA69517.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS6538.1; -. [Q12986-1]
DR   CCDS; CCDS6540.1; -. [Q12986-3]
DR   PIR; I38869; I38869.
DR   RefSeq; NP_002495.2; NM_002504.5. [Q12986-1]
DR   RefSeq; NP_667345.1; NM_147134.3. [Q12986-3]
DR   SMR; Q12986; -.
DR   BioGRID; 110865; 429.
DR   ELM; Q12986; -.
DR   IntAct; Q12986; 15.
DR   STRING; 9606.ENSP00000368856; -.
DR   iPTMnet; Q12986; -.
DR   PhosphoSitePlus; Q12986; -.
DR   BioMuta; NFX1; -.
DR   DMDM; 189047116; -.
DR   EPD; Q12986; -.
DR   jPOST; Q12986; -.
DR   MassIVE; Q12986; -.
DR   MaxQB; Q12986; -.
DR   PaxDb; Q12986; -.
DR   PeptideAtlas; Q12986; -.
DR   PRIDE; Q12986; -.
DR   ProteomicsDB; 59082; -. [Q12986-1]
DR   ProteomicsDB; 59083; -. [Q12986-2]
DR   ProteomicsDB; 59084; -. [Q12986-3]
DR   Antibodypedia; 25201; 135 antibodies.
DR   DNASU; 4799; -.
DR   Ensembl; ENST00000318524; ENSP00000317695; ENSG00000086102. [Q12986-3]
DR   Ensembl; ENST00000379540; ENSP00000368856; ENSG00000086102. [Q12986-1]
DR   GeneID; 4799; -.
DR   KEGG; hsa:4799; -.
DR   UCSC; uc003zso.4; human. [Q12986-1]
DR   CTD; 4799; -.
DR   DisGeNET; 4799; -.
DR   GeneCards; NFX1; -.
DR   HGNC; HGNC:7803; NFX1.
DR   HPA; ENSG00000086102; Low tissue specificity.
DR   MIM; 603255; gene.
DR   neXtProt; NX_Q12986; -.
DR   OpenTargets; ENSG00000086102; -.
DR   PharmGKB; PA31608; -.
DR   VEuPathDB; HostDB:ENSG00000086102.18; -.
DR   eggNOG; KOG1952; Eukaryota.
DR   GeneTree; ENSGT00940000156325; -.
DR   HOGENOM; CLU_005714_1_2_1; -.
DR   InParanoid; Q12986; -.
DR   OMA; HPCEHPP; -.
DR   OrthoDB; 299100at2759; -.
DR   PhylomeDB; Q12986; -.
DR   TreeFam; TF105889; -.
DR   PathwayCommons; Q12986; -.
DR   SIGNOR; Q12986; -.
DR   BioGRID-ORCS; 4799; 11 hits in 1016 CRISPR screens.
DR   ChiTaRS; NFX1; human.
DR   GeneWiki; NFX1; -.
DR   GenomeRNAi; 4799; -.
DR   Pharos; Q12986; Tbio.
DR   PRO; PR:Q12986; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q12986; protein.
DR   Bgee; ENSG00000086102; Expressed in buccal mucosa cell and 227 other tissues.
DR   Genevisible; Q12986; HS.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IBA:GO_Central.
DR   GO; GO:0001227; F:DNA-binding transcription repressor activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0003723; F:RNA binding; HDA:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II transcription regulatory region sequence-specific DNA binding; IDA:NTNU_SB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:ARUK-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0045347; P:negative regulation of MHC class II biosynthetic process; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:ARUK-UCL.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:ARUK-UCL.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IBA:GO_Central.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:ProtInc.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   CDD; cd02643; R3H_NF-X1; 1.
DR   Gene3D; 3.30.1370.50; -; 1.
DR   InterPro; IPR034078; NFX1_fam.
DR   InterPro; IPR001374; R3H_dom.
DR   InterPro; IPR036867; R3H_dom_sf.
DR   InterPro; IPR034076; R3H_NF-X1.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR000967; Znf_NFX1.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   PANTHER; PTHR12360; PTHR12360; 1.
DR   Pfam; PF01424; R3H; 1.
DR   Pfam; PF01422; zf-NF-X1; 8.
DR   SMART; SM00393; R3H; 1.
DR   SMART; SM00184; RING; 1.
DR   SMART; SM00438; ZnF_NFX; 9.
DR   SUPFAM; SSF82708; SSF82708; 1.
DR   PROSITE; PS51061; R3H; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; DNA-binding; Host-virus interaction;
KW   Metal-binding; Nucleus; Phosphoprotein; Reference proteome; Repeat;
KW   Repressor; Transcription; Transcription regulation; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..1120
FT                   /note="Transcriptional repressor NF-X1"
FT                   /id="PRO_0000055979"
FT   DOMAIN          994..1062
FT                   /note="R3H"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00382"
FT   ZN_FING         358..409
FT                   /note="RING-type; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   ZN_FING         453..471
FT                   /note="NF-X1-type 1"
FT   ZN_FING         506..525
FT                   /note="NF-X1-type 2"
FT   ZN_FING         567..586
FT                   /note="NF-X1-type 3"
FT   ZN_FING         632..655
FT                   /note="NF-X1-type 4"
FT   ZN_FING         694..713
FT                   /note="NF-X1-type 5"
FT   ZN_FING         721..740
FT                   /note="NF-X1-type 6"
FT   ZN_FING         832..854
FT                   /note="NF-X1-type 7"
FT   ZN_FING         863..884
FT                   /note="NF-X1-type 8"
FT   REGION          9..26
FT                   /note="Interaction with PABPC1 and PABC4"
FT                   /evidence="ECO:0000269|PubMed:17267499"
FT   COMPBIAS        1084..1089
FT                   /note="Poly-Pro"
FT   MOD_RES         50
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         82
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:B1AY10"
FT   MOD_RES         95
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         129
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:B1AY10"
FT   MOD_RES         150
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         326
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         809..833
FT                   /note="FRSNIPCHLVDISCGLPCSATLPCG -> QSHYWASTQKKRSHYMKKIPAHA
FT                   CL (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_033682"
FT   VAR_SEQ         834..1120
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_033683"
FT   VAR_SEQ         1014..1024
FT                   /note="GKNSKKSHSFP -> VEVETSHWTFL (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.1"
FT                   /id="VSP_033684"
FT   VAR_SEQ         1025..1120
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.1"
FT                   /id="VSP_033685"
FT   VARIANT         731
FT                   /note="H -> Y (in dbSNP:rs5017299)"
FT                   /id="VAR_043380"
FT   VARIANT         760
FT                   /note="P -> S (in dbSNP:rs2860036)"
FT                   /id="VAR_043381"
FT   VARIANT         1086
FT                   /note="P -> Q (in dbSNP:rs2274866)"
FT                   /id="VAR_043382"
FT   MUTAGEN         20
FT                   /note="F->A: Reduces PABPC1 and PABC4 binding."
FT                   /evidence="ECO:0000269|PubMed:17267499"
FT   CONFLICT        179
FT                   /note="G -> A (in Ref. 1; AAA69517)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        186
FT                   /note="G -> E (in Ref. 1; AAA69517)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        312
FT                   /note="Q -> P (in Ref. 1; AAA69517)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        419..420
FT                   /note="YT -> FS (in Ref. 1; AAA69517)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        560
FT                   /note="I -> T (in Ref. 1; AAA69517)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        653
FT                   /note="C -> V (in Ref. 1; AAA69517)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        678
FT                   /note="E -> EA (in Ref. 2; BAF84332)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        714
FT                   /note="I -> N (in Ref. 1; AAA69517)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        786
FT                   /note="C -> G (in Ref. 1; AAA69517)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1120 AA;  124395 MW;  F2203BE1DB6437E6 CRC64;
     MAEAPPVSGT FKFNTDAAEF IPQEKKNSGL NCGTQRRLDS NRIGRRNYSS PPPCHLSRQV
     PYDEISAVHQ HSYHPSGSKP KSQQTSFQSS PCNKSPKSHG LQNQPWQKLR NEKHHIRVKK
     AQSLAEQTSD TAGLESSTRS ESGTDLREHS PSESEKEVVG ADPRGAKPKK ATQFVYSYGR
     GPKVKGKLKC EWSNRTTPKP EDAGPESTKP VGVFHPDSSE ASSRKGVLDG YGARRNEQRR
     YPQKRPPWEV EGARPRPGRN PPKQEGHRHT NAGHRNNMGP IPKDDLNERP AKSTCDSENL
     AVINKSSRRV DQEKCTVRRQ DPQVVSPFSR GKQNHVLKNV ETHTGSLIEQ LTTEKYECMV
     CCELVRVTAP VWSCQSCYHV FHLNCIKKWA RSPASQADGQ SGWRCPACQN VSAHVPNTYT
     CFCGKVKNPE WSRNEIPHSC GEVCRKKQPG QDCPHSCNLL CHPGPCPPCP AFMTKTCECG
     RTRHTVRCGQ AVSVHCSNPC ENILNCGQHQ CAELCHGGQC QPCQIILNQV CYCGSTSRDV
     LCGTDVGKSD GFGDFSCLKI CGKDLKCGNH TCSQVCHPQP CQQCPRLPQL VRCCPCGQTP
     LSQLLELGSS SRKTCMDPVP SCGKVCGKPL PCGSLDFIHT CEKLCHEGDC GPCSRTSVIS
     CRCSFRTKEL PCTSLKSEDA TFMCDKRCNK KRLCGRHKCN EICCVDKEHK CPLICGRKLR
     CGLHRCEEPC HRGNCQTCWQ ASFDELTCHC GASVIYPPVP CGTRPPECTQ TCARVHECDH
     PVYHSCHSEE KCPPCTFLTQ KWCMGKHEFR SNIPCHLVDI SCGLPCSATL PCGMHKCQRL
     CHKGECLVDE PCKQPCTTPR ADCGHPCMAP CHTSSPCPVT ACKAKVELQC ECGRRKEMVI
     CSEASSTYQR IAAISMASKI TDMQLGGSVE ISKLITKKEV HQARLECDEE CSALERKKRL
     AEAFHISEDS DPFNIRSSGS KFSDSLKEDA RKDLKFVSDV EKEMETLVEA VNKGKNSKKS
     HSFPPMNRDH RRIIHDLAQV YGLESVSYDS EPKRNVVVTA IRGKSVCPPT TLTGVLEREM
     QARPPPPIPH HRHQSDKNPG SSNLQKITKE PIIDYFDVQD
//
